HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott recalls infant formula

This article was originally published in The Tan Sheet

Executive Summary

Abbott's Ross Products Division announces Sept. 15 it is voluntarily recalling some lots of liquid ready-to-feed infant formula distributed between May 18 and Sept. 5. One lot of Similac Alimentum Advance liquid ready-to-feed infant formula, use by May 1, 2007; two lots of Similac Advance with Iron liquid ready-to-feed infant formula, use by Nov. 1, 2007; and one lot of Similac Advance Hospital Discharge Kits are all being recalled due to an isolated bottle defect the release states. An Abbott spokesperson said some of the bottles are missing a layer that prevents air from getting to the formula and thus may lead the vitamin C to oxidize, or breakdown. If consumers have the listed products they should contact Abbott at 1-800-624-3412. Abbott discovered the problem as a result of consumer complaints for an unusually dark formula color the release states...

You may also be interested in...



Abbott Recalls Infant Formula Made At Facility FDA Is Investigating For Bacterial Contamination

Abbott Labs recalls Similac, Alimentum and EleCare brand formula powders made at Sturgis, MI, plant. FDA says complaints about Abbott’s formulas included three reports of Cronobacter sakazakii infections, with one death potentially linked, and one of Salmonella Newport infection.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS125678

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel